Status:
COMPLETED
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
Lead Sponsor:
Bayer
Conditions:
Metastatic Colorectal Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is an observational study in which data already collected from patients with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bow...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of mCRC between 1 JAN 2013 and 31 DEC 2022 who initiated regorafenib monotherapy up to 14 days prior or after mCRC diagnosis and during the patient selection period (1 JUL 2013 to 31 DEC 2022).
- Adult patients (≥18 years old) at index date (date of first regorafenib treatment).
- Patients with at least one recorded visit, laboratory test, or other recorded electronic medical record (EMR) entry (e.g., treatment) in the Flatiron network at least 3 months prior to the index date, unless the patient was diagnosed with mCRC within the last 3 months.
Exclusion
- Patients who had a diagnosis or recorded history of gastrointestinal stromal tumor (GISC), hepatocellular cancer (HCC), or other primary cancers (except non-melanoma skin cancers) during the 6-month period on or prior to the index date.
- For analyses of long-term responders, patients will be excluded if treatment duration \<5 and \<4 months for treatment completers, or treatment duration \<5 and \<4 months at last visit date for non-completers.
Key Trial Info
Start Date :
August 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 27 2025
Estimated Enrollment :
2326 Patients enrolled
Trial Details
Trial ID
NCT06029010
Start Date
August 31 2023
End Date
January 27 2025
Last Update
February 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, New Jersey, United States, 07981